Alpha 2.0
Login Register
» Authors » Mark Cronin

Mark Cronin

Explore the profile of Mark Cronin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 826
Followers 0
Related Specialties
Toxicology
Pharmacology
Chemistry
Top 10 Co-Authors
Folkert Reck
Catherine Mahony
Bolin Geng
Dagmar Bury
Joseph V Newman
John Breen
Gerry Kenna
David E Ehmann
Andreas Schepky
Janelle Comita-Prevoir
Published In
Regul Toxicol Pharmacol
J Med Chem
Toxicol Sci
Altern Lab Anim
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
11.
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy
Dougherty T, Nayar A, Newman J, Hopkins S, Stone G, Johnstone M, et al.
Antimicrob Agents Chemother . 2014 Feb; 58(5):2657-64. PMID: 24566174
The need for new antibiotics that address serious Gram-negative infections is well recognized. Our efforts with a series of novel bacterial type II topoisomerase inhibitors (NBTIs) led to the discovery...
12.
QSAR modeling: where have you been? Where are you going to?
Cherkasov A, Muratov E, Fourches D, Varnek A, Baskin I, Cronin M, et al.
J Med Chem . 2013 Dec; 57(12):4977-5010. PMID: 24351051
Quantitative structure-activity relationship modeling is one of the major computational tools employed in medicinal chemistry. However, throughout its entire history it has drawn both praise and criticism concerning its reliability,...
13.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile
Reck F, Alm R, Brassil P, Newman J, Ciaccio P, McNulty J, et al.
J Med Chem . 2012 Jul; 55(15):6916-33. PMID: 22779424
Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance...
14.
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity
Reck F, Alm R, Brassil P, Newman J, DeJonge B, Eyermann C, et al.
J Med Chem . 2011 Oct; 54(22):7834-47. PMID: 21999508
Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance...
15.
Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010
Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, et al.
Arch Toxicol . 2011 May; 85(5):367-485. PMID: 21533817
The 7th amendment to the EU Cosmetics Directive prohibits to put animal-tested cosmetics on the market in Europe after 2013. In that context, the European Commission invited stakeholder bodies (industry,...
16.
Skin sensitisation and epidermal disposition: the relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report and recommendations of ECVAM workshop 59
Basketter D, Pease C, Kasting G, Kimber I, Casati S, Cronin M, et al.
Altern Lab Anim . 2007 Apr; 35(1):137-54. PMID: 17411362
No abstract available.